StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Favorable GTN Adjustments Related to Prior Period Sales by Quarter

Favorable GTN Adjustments Related to Prior Period Sales (legacy disclosure) ($M) ($M)

Amgen Favorable GTN Adjustments Related to Prior Period Sales: $0M in Q4 2018. No newer figure appears in the documents we track.

Latest, Q4 2018
0
Period ended Dec 31, 2018
Change on a year earlier
–
History
4 quarters
Since Q1 2018
Sources
4
Documents cited below

Where the Q4 2018 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2019-02-13) ↗

Reported in Form 10-Q / 10-K Revenue Recognition Footnote (XBRL).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFavorable GTN Adjustments Related to Prior Period Sales (legacy disclosure) ($M) ($M)Year on yearSource
Q4 2018Dec 31, 20180–Form 10-K (filed 2019-02-13) ↗
Q3 2018Sep 30, 20180–Form 10-Q (filed 2018-10-31) ↗
Q2 2018Jun 30, 20180–Form 10-Q (filed 2018-07-27) ↗
Q1 2018Mar 31, 20180–Form 10-Q (filed 2018-04-25) ↗

Cite this data

StockData. (2026). Amgen Favorable GTN Adjustments Related to Prior Period Sales ($M), quarterly Q1 2018–Q4 2018 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gtn-prior-adj

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.